Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults
Circulation: Cardiovascular Quality and Outcomes · 2024
DOI: 10.1161/circoutcomes.123.010685 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Circulation: Cardiovascular Quality and Outcomes, 2024. Verfasst von Antoine Fayol und 13 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique-Hôpitaux de Paris, Departement of Cardiology, Hôpital Européen Georges-Pompidou, France (A.F., E.P., V.T., C.C., O.W., N.D.). Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Registries, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
BACKGROUND: Older people are underrepresented in randomized trials. The association between lipid-lowering therapy (LLT) and its intensity after acute myocardial infarction and long-term mortality in this population deserves to be assessed. METHODS: The FAST-MI (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) program consists of nationwide French surveys including all patients admitted for acute myocardial infarction ≤48 hours from onset over a 1- to 2-month period in 2005, 2010, and 2015, with long-term follow-up. Numerous data were collected and a centralized 10-year follow-up was organized. The present analysis focused on the association between prescription of LLT (atorvastatin ≥40 mg or equivalent, or any combination of statin and ezetimibe) and 5-year mortality in patients aged ≥80 years discharged alive. Cox multivariable analysis and propensity score matching were used to adjust for baseline differences. RESULTS: Among the 2258 patients aged ≥80 years (mean age, 85±4 years; 51% women; 39% ST-segment elevation myocardial infarction; 58% with percutaneous coronary intervention), 415 were discharged without LLT (18%), 866 with conventional doses (38%), and 977 with high-dose LLT (43%). Five-year survival was 36%, 47.5%, and 58%, respectively. Compared with patients without LLT, high-dose LLT was significantly associated with lower 5-year mortality (adjusted hazard ratio, 0.78 [95% CI, 0.66–0.92]), whereas conventional-intensity LLT was not (adjusted hazard ratio, 0.93 [95% CI, 0.80–1.09]). In propensity score-matched cohorts (n=278 receiving high-intensity LLT and n=278 receiving no statins), 5-year survival was 52% with high-intensity LLT at discharge and 42% without statins (hazard ratio, 0.78 [95% CI, 0.62–0.98]). CONCLUSIONS: In these observational cohorts, high-intensity LLT at discharge after acute myocardial infarction was associated with reduced all-cause mortality at 5 years in an older adult population. These results suggest that high-intensity LLT should not be denied to patients on the basis of old age. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT00673036, NCT01237418, and NCT02566200.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Assistance Publique-Hôpitaux de Paris, Departement of Cardiology, Hôpital Européen Georges-Pompidou, France (A.F., E.P., V.T., C.C., O.W., N.D.).
- University Paris Cité, France (A.F., E.P., V.T., C.C., O.W., N.D.).
- Department of Cardiology, University Hospital Jean-Minjoz, Besançon, France (F.S.).
- Department of Cardiology, Toulouse Rangueil University Hospital, Institut National pour la Santé Et la Recherche Médicale Unité Mixte de Recherche, Toulouse cedex, France Emergency Department, Rangueil Hospital, Toulous…
- Department of Cardiology, Hospital of Chartres, France (F.A.).
- Department of Cardiology, Heart and Lung Institute, University Hospital of Lille, France (G.L.).
ORCID-Profile: Antoine Fayol, François Schiele, Etienne Puymirat, Chekrallah Chamandi, Gilles Lemesle, Guillaume Cayla, Orianne Weizman, Tabassome Simon, Nicolas Danchin
Zitieren
APA
Fayol, A., Schiele, F., Ferrières, J., Puymirat, E., Bataille, V., Tea, V., Chamandi, C., Albert, F., Lemesle, G., Cayla, G., Weizman, O., Simon, T., Danchin, N., & FAST-MI Investigators (2024). Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.123.010685
Vancouver
Fayol A, Schiele F, Ferrières J, Puymirat E, Bataille V, Tea V, et al. Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults. Circulation: Cardiovascular Quality and Outcomes. 2024. doi:10.1161/circoutcomes.123.010685
BibTeX
@article{Fayol2024,
author = {Fayol, Antoine and Schiele, François and Ferrières, Jean and Puymirat, Etienne and Bataille, Vincent and Tea, Victoria and Chamandi, Chekrallah and Albert, Franck and Lemesle, Gilles and Cayla, Guillaume and Weizman, Orianne and Simon, Tabassome and Danchin, Nicolas and FAST-MI Investigators, FAST-MI Investigators},
title = {Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults},
journal = {Circulation: Cardiovascular Quality and Outcomes},
year = {2024},
doi = {10.1161/circoutcomes.123.010685}
}
EUVIMED